To appraise the clinical and cost effectiveness of nivolumab in combination with platinum-doublet chemotherapy within its marketing authorisation for untreated PD-L1-negative non-small-cell lung cancer.
The National Institute for Health and Clinical Excellence (NICE) has been invited to carry out an appraisal of nivolumab in combination with platinum-doublet chemotherapy for untreated non-small-cell lung cancer. We have recently invited stakeholders to respond to a written consultation on the draft scope which closed on 8 August 2019. The company developing nivolumab, Bristol-Myers Squibb, has advised NICE that they are unable to provide an evidence submission within the scheduled timelines. In light of this information NICE will be suspending this appraisal. If you have any comments or concerns please contact the Project Manager for this appraisal Kate Moore on TACommD@nice.org.uk
 
Status Suspended
Process STA pre-2018
ID number 1135

Project Team

Project lead Michelle Adhemar

Email enquiries

Timeline

Key events during the development of the guidance:

Date Update
08 August 2019 Suspended, The National Institute for Health and Clinical Excellence (NICE) has been invited to carry out an appraisal of nivolumab in combination with platinum-doublet chemotherapy for untreated non-small-cell lung cancer. We have recently invited stakeholders to respond to a written consultation on the draft scope which closed on 8 August 2019. The company developing nivolumab, Bristol-Myers Squibb, has advised NICE that they are unable to provide an evidence submission within the scheduled timelines. In light of this information NICE will be suspending this appraisal. If you have any comments or concerns please contact the Project Manager for this appraisal Kate Moore on TACommD@nice.org.uk
18 July 2019 Draft scope documents
11 September 2017 - 09 October 2017 Consultation on suggested remit, draft scope and provisional matrix of consultees and commentators
12 September 2017 In progress, In progress

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance